The role of apoptosis and chronic prostatitis in the pathogenesis of benign prostatic hyperplasia;Znaczenie apoptozy i przewlekłego zapalenia gruczołu krokowego w patogenezie łagodnego rozrostu

Polski Merkuriusz Lekarski

Volumn 17, Issue 100, 2004, Pages 307-310

  Pawlicki, Bohdan ^a   Zieliński, Henryk ^b   Da̧browski, Marek ^c  

^a Szpital im GNarutowicza ^*  (Poland)

^b MILITARY INSTITUTE OF MEDICINE   (Poland)

^c MILITARY INSTITUTE OF HYGIENE AND EPIDEMIOLOGY   (Poland)

Author keywords

Apoptosis; Benign prostatic hyperplasia; Chronic prostatitis

Indexed keywords

GROWTH FACTOR;

AGING; APOPTOSIS; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CHRONIC PROSTATITIS; HUMAN; IMMUNE SYSTEM; MALE; NEUROENDOCRINE SYSTEM; PARACRINE SIGNALING; PROSTATE HYPERTROPHY; REVIEW;

APOPTOSIS; CHRONIC DISEASE; HUMANS; MALE; PROSTATIC HYPERPLASIA; PROSTATITIS;

EID: 9144220210     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Borkowski A., Borówka A.: Choroby gruczołu krokowego. PZWL. Warszawa. 1997, 89-93.
2. Bozec A., Ruffion A., Decaussin M. i wsp.: Caspases are involved in benign prostatic hyperplasia (BPH) induced apoptosis by finasteride. XVIII Congress of European Association of Urology, Madrid 2003, CD-Rom, 0329.html.
3. Buchanan G., Greenberg N.M., Scher H.I.: Collocation of androgen receptor gene mutations in prostate cancer. Clin. Cancer Res., 2001, 7, 1273-1281.
4. Cabuk M., Balci M., Aydin M. i wsp.: The comparison of the apoptosis of rat prostate tissue which is formed by high dose of cox-2 inhibitor with the apoptosis that is formed by medical castration. 98th American Urological Association Annual Meeting, Chicago. 2003, CD-Rom 833.
5. Carson III C., Rittmaster R.: The role of dihydrotestosterone in benign prostatic hyperplasia. Urology, 2003, 61 suppl 4a, 2-7.
6. Cunha G.R.: Role of mesenchymal-epithelial interactions in normal and abnormal development of mammary gland and prostatae. Cancer, 1994, 74, 1030-1044.
7. Demande S.R., Lin X.S., Isaacs J.T.: Role of programmed (apoptotic) cell death during the progression of therapy for prostate cancer. Prostate, 1996, 28, 251-265.
8. Erdogru T., Ciftcioglu M.A., Emreoglu I. i wsp.: Apoptotic and proliferative index after alpha-1-adrenoceptor antagonist and/or finasteride treatment in benign prostatic hyperplasia. Urol. Int., 2002, 69, 287-292.
9. Foster C.S.: Pathology of benign prostatic hyperplasia. Prostate, 2000, 9, 4-14.
10. Freeman M.R., Scheneck F.X., Gagnon M.: Peripheral blood T lymphocytes and T cells infiltrating human cancers express vascular endothelial growth factor potential role for T cells in angiogenesis. Cancer Res., 1995, 55, 4140-4145.
11. Gestenblith R.E., Seftel A.D., Mac Lennan G.T. i wsp.: Distribution of chronic prostatitis inradical prostatectomy specimens with up-regulation of bcl-2 in areas of inflammation. J. Urol., 2002, 167, 2267-2270.
12. Gewies A., Rokhlin O.W., Cohen M.B.: Cytochromec is involved in Fas-mediated apoptosis of prostatic carcinoma cell lines. Cancer Res., 2000, 60, 2163-2168.
13. Haldar S., Basu A., Croce C.M.: Serine-70 is one of the critical sites for drug-induced bcl-2 phosphorylation in cancer cells. Cancer Res., 1998, 58, 1609-1615.
14. Haldar S., Chintapalli J., Croce C.M.: Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res., 1996, 56, 1253-1255.
15. Harris D.R., Saville J.: Apoptosis in the prostate. Br J Urol., 1995, 75 suppl. 1, 27-33.
16. Isaacs J.T., Coffey D.S.: Etiology and disease processes of benign prostatic hyperplasia. Prostate, suppl. 1989, 2, 33-50.
17. Kessler O.J., Keisari Y., Servadio C.: Role of chronic inflammation in the promotion of prostatic hyperplasia in rats. J. Urol., 1998, 159, 1049-1054.
18. Kyprianou N., Benning C.M.: Suppression of human prostate cancer cell lines by alfa1 adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res., 2000, 60, 4550-4555.
19. Kyprianou N., Tu H., Jacobs S.C.: Apoptotic versus proliferate activities in human benign prostatic hyperplasia. Hum. Pathol., 1996, 27, 668-675.
20. Lee C., Kozlowski J.M., Grayhack J.T.: Intrinisic and extrinisic factors controlling benign prostatic growth. Prostate, 1997, 31, 131-138.
21. Liu A.Y., Latray L., Van Den Engh D.: Changes in cell surface molecules associated with in vitro culture of prostatic stromal cells. Prostate, 2000, 44, 303-312.
22. Miguel M.P., Royuela M., Bethencourt F.R. i wsp.: Immunoexpression of tumor necrosis factor- and its receptors 1 and 2 correlates with proliferation/apoptosis equilibrium in normal, hyperplastic and carcinomatous human prostate. Cytokine, 2000, 12, 535-538.
23. Nickel J.C., Downey J., Young I.: Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. Br. J. Urol., 1999, 84, 976-981.
24. Niu Y., Xu Y., Zhang J.: Proliferation and differentiation of prostatic stromal cells. BJU Int., 2001, 87, 386-393.
25. Panvichian R., Orth K., Pilat M.J.: i wsp.: Signaling network of paclitaxel-induced apoptosis in the LNCaP prostate cancer cell line. Urology, 1999, 54, 746-752.
26. Powll W.C., Fingleton B., Wilson C.L. i wsp.: The metalloproteinase matrilysin proteolytically generates active soluble fas ligand and potentiates epithelial cell apoptosis. Curr. Biol., 1999, 9, 1441-1447.
27. Rane A.: Endocrine and adrenergic pharmacological intervention in disease of the prostatae. Br. J. Clin. Pharmacol., 1998, 45, 329-337.
28. Ronan N.T., Coffey R., Wiliam G. i wsp.: Signaling for the caspase: their role in prostatae cell apoptosis. J. Urol., 2001, 65, 5-14.
29. Royle J., Ansell I., Ross J. i wsp.: NO-NASIDS induce apoptosis in human prostate cell systems. XVIII Congress of European Association of Urology, Madrid 2003, CD-Rom 0330.html.
30. Royuela M., Arenas M.I., Bethencourt F.R. i wsp.: Regulation of proliferation/apoptosis equilibrium by mitogen-activated protein kinases in normal, hyperplastic and carcinomatous human prostate. Human Path., 2002, 33, 299-306.
31. Royuela M., Miguel M.P., Bethencourt F.R.: IL-2, its receptors and bcl-2 and bax genes in normal, hyperplastic and carcinomatous human prostates: Immunohistochemical comparative analysis. Growth Factors, 2000, 18, 135-146.
32. Steiner M.S.: Review of peptide growth factors in benign prostatic hyperplasia and urological malignancy. J. Urol., 1995, 153, 1085-1096.
33. Thompson T.C., Yang G.: Regulation of apoptosis in prostatic disease. Prostatae, 2000, 9, 25-8.
34. Tricoli J.V., Winter C.L., Hanlon A.L. i wsp.: Radical differences in insulin-like growth factor binding protein-3 in men at increased risk of prostatae cancer. Urology, 1999, 54, 178-182.
35. Walsh P.C., Retic A.B., Vaughan E.D., Wein A.J.: Campblell's Urology. Philadelphia: Elsevier Science 2003, Eith Edition CD-Rom.
36. Waters D.J., Shen S., Cooley D.M. i wsp.: Effects of dietary selenium supplementation on DNA damage and apoptosis in canine prostate. J. Nat. Cancer Inst., 2003, 95, 237-241.
37. Wolski Z., Drewa T., Wozniak A. i wsp.: Ocena ekspresji białka błonowego Fas (CD95, Apo-1) w hodowli pierwotnej komórek nabłonka sterczau chorych z łagodnym rozrostem i rakiem przy użyciu cytometru przepływowego. Urologia Polska, 2003, 56, 23-27.
38. Yamashita M., Zhang X., Shiraishi T. i wsp.: Determination of percent area density of epithelial and stromal components in development of prostatic hyperplasia in spontaneously hypertensive rats. Urology, 2003, 61, 484-489.